Zacks Research Analysts Reduce Earnings Estimates for CRL

Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) - Analysts at Zacks Research dropped their Q1 2025 earnings estimates for Charles River Laboratories International in a report released on Thursday, April 10th. Zacks Research analyst R. Department now anticipates that the medical research company will post earnings of $2.06 per share for the quarter, down from their previous forecast of $2.07. The consensus estimate for Charles River Laboratories International's current full-year earnings is $9.36 per share. Zacks Research also issued estimates for Charles River Laboratories International's Q2 2025 earnings at $2.29 EPS, Q3 2025 earnings at $2.40 EPS, Q4 2025 earnings at $2.55 EPS, FY2025 earnings at $9.30 EPS, Q1 2026 earnings at $2.44 EPS, Q3 2026 earnings at $2.65 EPS, Q4 2026 earnings at $2.68 EPS, FY2026 earnings at $10.22 EPS, Q1 2027 earnings at $2.65 EPS and FY2027 earnings at $10.91 EPS.

A number of other equities analysts also recently issued reports on the stock. Citigroup upgraded shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and increased their price objective for the company from $155.00 to $175.00 in a research note on Tuesday, March 4th. Barclays lowered their price target on shares of Charles River Laboratories International from $160.00 to $145.00 and set an "equal weight" rating on the stock in a report on Thursday, April 10th. Mizuho reduced their target price on Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating for the company in a report on Wednesday, April 9th. JPMorgan Chase & Co. cut their target price on Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating for the company in a research note on Thursday, February 20th. Finally, Morgan Stanley reduced their price objective on Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating on the stock in a research note on Wednesday, February 5th. One investment analyst has rated the stock with a sell rating and sixteen have assigned a hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $182.00.

Charles River Laboratories International Trading Down 0.6 %

Shares of NYSE:CRL traded down $0.62 during trading on Friday, reaching $105.30. The company's stock had a trading volume of 580,583 shares, compared to its average volume of 879,547. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. The firm's 50 day simple moving average is $154.31 and its two-hundred day simple moving average is $175.73. The stock has a market capitalization of $5.17 billion, a PE ratio of 702.00, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. Charles River Laboratories International has a 12 month low of $91.86 and a 12 month high of $254.15.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, topping analysts' consensus estimates of $2.50 by $0.16. The company had revenue of $1 billion for the quarter, compared to analysts' expectations of $983.63 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. Charles River Laboratories International's revenue for the quarter was down 1.1% compared to the same quarter last year. During the same period last year, the firm earned $2.46 EPS.

Insider Transactions at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 4,400 shares of the firm's stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $162.50, for a total value of $715,000.00. Following the sale, the executive vice president now owns 20,013 shares in the company, valued at approximately $3,252,112.50. This trade represents a 18.02 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO James C. Foster purchased 6,075 shares of the business's stock in a transaction on Thursday, February 20th. The stock was purchased at an average cost of $165.01 per share, with a total value of $1,002,435.75. Following the acquisition, the chief executive officer now owns 183,639 shares in the company, valued at approximately $30,302,271.39. This represents a 3.42 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.30% of the stock is owned by insiders.

Institutional Trading of Charles River Laboratories International

Several institutional investors and hedge funds have recently bought and sold shares of the business. Rothschild Investment LLC lifted its holdings in shares of Charles River Laboratories International by 480.0% in the first quarter. Rothschild Investment LLC now owns 174 shares of the medical research company's stock worth $26,000 after acquiring an additional 144 shares during the last quarter. Versant Capital Management Inc raised its position in shares of Charles River Laboratories International by 1,071.4% in the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company's stock worth $30,000 after acquiring an additional 150 shares in the last quarter. Pinnacle Bancorp Inc. grew its holdings in Charles River Laboratories International by 52.0% in the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock worth $35,000 after purchasing an additional 65 shares during the period. Optiver Holding B.V. bought a new stake in shares of Charles River Laboratories International during the fourth quarter valued at approximately $37,000. Finally, GeoWealth Management LLC lifted its position in Charles River Laboratories International by 311.5% in the 4th quarter. GeoWealth Management LLC now owns 251 shares of the medical research company's stock valued at $46,000 after acquiring an additional 190 shares in the last quarter. Institutional investors own 98.91% of the company's stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).